<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="07/04/01" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9234742" creator="Yumiko Katsu">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>9234742</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Opposite effects of the <term sem="Protein_molecule" id="T1" lex="acute_promyelocytic_leukemia_PML-retinoic_acid_receptor_alpha">acute promyelocytic leukemia PML-retinoic acid receptor alpha</term> (<term sem="Protein_molecule" id="T2" lex="RAR_alpha">RAR alpha</term>) and <term sem="Protein_molecule" id="T3" lex="PLZF-RAR_alpha_fusion_protein">PLZF-RAR alpha <term sem="Protein_molecule" id="A1">fusion proteins</term></term> on <term sem="Other" id="T4" lex="retinoic_acid_signalling"><term sem="Organic_compound_other" id="T5" lex="retinoic_acid">retinoic acid</term> signalling</term>.</sentence>
<event id="E1">
<type class="Regulation" />
<theme idref="T4" />
<cause idref1="A1" idref="T1" />
<clue><clueType>Opposite effects</clueType> <linkCause>of</linkCause> the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins <linkTheme>on</linkTheme> retinoic acid signalling.</clue>
</event>
<event id="E2">
<type class="Regulation" />
<theme idref="T4" />
<cause idref="T3" />
<clue><clueType>Opposite effects</clueType> <linkCause>of</linkCause> the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins <linkTheme>on</linkTheme> retinoic acid signalling.</clue>
</event>
<event id="E53">
<type class="Cell_communication" />
<theme idref="T5" />
<clue>Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid <clueType>signalling</clueType>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Fusion proteins involving the <term sem="Organic_compound_other" id="T6" lex="retinoic_acid">retinoic acid</term> <term sem="Protein_molecule" id="T7" lex="receptor_alpha">receptor alpha</term> (<term sem="Protein_molecule" id="T8" lex="RAR_alpha">RAR alpha</term>) and the <term sem="Protein_molecule" id="T9" lex="PML">PML</term> or <term sem="Protein_molecule" id="T10" lex="PLZF_nuclear_protein">PLZF nuclear protein</term> are the genetic markers of <term sem="Other" id="T11" lex="acute_promyelocytic_leukemia">acute promyelocytic leukemias</term> (<term sem="Other" id="T12" lex="APL">APLs</term>).</sentence>
<sentence id="S3"><term sem="Other" id="A4"><term sem="Other" id="T13" lex="APL">APLs</term> with</term> the <term sem="Protein_molecule" id="T14" lex="PML-RAR_alpha">PML-RAR alpha</term> or the <term sem="Protein_molecule" id="T16" lex="PLZF-RAR_alpha_fusion_protein">PLZF-RAR alpha fusion protein</term> are phenotypically indistinguishable except that they differ in their sensitivity to <term sem="Other" id="T17" lex="retinoic_acid_(RA)-induced_differentiation"><term sem="Organic_compound_other" id="T18" lex="retinoic_acid">retinoic acid</term> (<term sem="Organic_compound_other" id="A2">RA</term>)-induced <term sem="Other" id="A3">differentiation</term></term>: <term sem="Cell_natural" id="A5"><term sem="Protein_molecule" id="T19" lex="PML-RAR_alpha">PML-RAR alpha</term> blasts</term> are sensitive to <term sem="Organic_compound_other" id="T20" lex="RA">RA</term> and patients enter disease remission after <term sem="Other" id="T21" lex="RA_treatment"><term sem="Organic_compound_other" id="T22" lex="RA">RA</term> treatment</term>, while <term sem="Multicellular_organism_natural" id="A6">patients with <term sem="Protein_molecule" id="T23" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term></term> do not.</sentence>
<event id="E3">
<type class="Positive_regulation" />
<theme idref="A3" />
<cause idref="A2" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-<clueType>induced</clueType> differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>NER T14 MOD</comment>
</event>
<event id="E4">
<type />
<theme idref1="T14" idref="A4" />
<cause idref="A2" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in <corefTheme>their</corefTheme> <clueType>sensitivity</clueType> <linkCause>to</linkCause> retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>NER T15 MOD, SENSITIVITY</comment>
</event>
<event id="E5">
<type />
<theme idref1="T16" idref="A4" />
<cause idref="A2" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in <corefTheme>their</corefTheme> <clueType>sensitivity</clueType> <linkCause>to</linkCause> retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>TPS A4, SENSITIVITY</comment>
</event>
<event id="E6">
<type />
<theme idref="A5" />
<cause idref="T20" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are <clueType>sensitive</clueType> <linkCause>to</linkCause> RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>SENSITIVITY</comment>
</event>
<event id="E7">
<type class="Artificial_process" />
<theme idref="T22" />
<theme idref="A5" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA <clueType>treatment</clueType>, while patients with PLZF-RAR alpha do not.</clue>
</event>
<event id="E8">
<type class="Negative_regulation" />
<theme idref="T13" />
<cause idref="E7" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter <corefTheme>disease</corefTheme> <clueType>remission</clueType> <linkCause>after</linkCause> RA treatment, while patients with PLZF-RAR alpha do not.</clue>
</event>
<event assertion="non-exist" id="E80">
<type />
<theme idref="A6" />
<cause idref="T20" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are <clueType>sensitive</clueType> <linkCause>to</linkCause> RA and patients enter disease remission after RA treatment, while patients with PLZF-RAR alpha do not.</clue>
<comment>SENSITIVITY</comment>
</event>
<event assertion="non-exist" id="E74">
<type class="Artificial_process" />
<theme idref="T22" />
<theme idref="A6" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter disease remission after RA <clueType>treatment</clueType>, while patients with PLZF-RAR alpha do not.</clue>
</event>
<event assertion="non-exist" id="E75">
<type class="Negative_regulation" />
<theme idref="T13" />
<cause idref="E74" />
<clue>APLs with the PML-RAR alpha or the PLZF-RAR alpha fusion protein are phenotypically indistinguishable except that they differ in their sensitivity to retinoic acid (RA)-induced differentiation: PML-RAR alpha blasts are sensitive to RA and patients enter <corefTheme>disease</corefTheme> <clueType>remission</clueType> <linkCause>after</linkCause> RA treatment, while patients with PLZF-RAR alpha do not.</clue>
</event>
<sentence id="S4">We here report that (i) like <term sem="Other" id="T24" lex="PML-RAR_alpha_expression"><term sem="Protein_molecule" id="T25" lex="PML-RAR_alpha">PML-RAR alpha</term> expression</term>, <term sem="Other" id="T26" lex="PLZF-RAR_alpha_expression"><term sem="Protein_molecule" id="T27" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term> expression</term> blocks terminal differentiation of <term sem="Cell_cultured" id="T28" lex="hematopoietic_precursor_cell_line">hematopoietic precursor cell lines</term> (<term sem="Cell_cultured" id="T29" lex="U937">U937</term> and <term sem="Cell_cultured" id="T30" lex="HL-60">HL-60</term>) in response to different stimuli (<term sem="Organic_compound_other" id="T31" lex="vitamin_D3">vitamin D3</term>, <term sem="Peptide" id="A101">transforming growth factor <term sem="Organic_compound_other" id="T32" lex="beta1">beta1</term></term>, and <term sem="Organic_compound_other" id="T33" lex="dimethyl_sulfoxide">dimethyl sulfoxide</term>); (ii) <term sem="Protein_molecule" id="T34" lex="PML-RAR_alpha">PML-RAR alpha</term>, but not <term sem="Protein_molecule" id="T35" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term>, increases <term sem="Other" id="T36" lex="RA_sensitivity"><term sem="Organic_compound_other" id="A7">RA</term> sensitivity</term> of <term sem="Cell_natural" id="T37" lex="hematopoietic_precursor_cell">hematopoietic precursor cells</term> and restores <term sem="Other" id="T38" lex="RA_sensitivity"><term sem="Organic_compound_other" id="A8">RA</term> sensitivity</term> of <term sem="Cell_natural" id="T39" lex="RA-resistant_hematopoietic_cell"><term sem="Organic_compound_other" id="A9">RA</term>-resistant <term sem="Cell_natural" id="A10">hematopoietic cells</term></term>; (iii) <term sem="Protein_molecule" id="T40" lex="PML-RAR_alpha">PML-RAR alpha</term> and <term sem="Protein_molecule" id="T41" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term> have similar <term sem="Organic_compound_other" id="T42" lex="RA">RA</term> binding affinities; and (iv) <term sem="Protein_molecule" id="T43" lex="PML-RAR_alpha">PML-RAR alpha</term> enhances the <term sem="Organic_compound_other" id="T44" lex="RA">RA</term> response of <term sem="DNA_family_or_group" id="T45" lex="RA_target_gene"><term sem="Organic_compound_other" id="T46" lex="RA">RA</term> target genes</term> (those for <term sem="Protein_molecule" id="T47" lex="RAR_beta">RAR beta</term>, <term sem="Protein_molecule" id="T48" lex="RAR_gamma">RAR gamma</term>, and <term sem="Protein_molecule" id="T49" lex="transglutaminase_type_II">transglutaminase type II</term> [<term sem="Protein_molecule" id="T50" lex="TGase">TGase</term>]) in vivo, while <term sem="Other" id="T51" lex="PLZF-RAR_alpha_expression"><term sem="Protein_molecule" id="T52" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term> expression</term> has either no effect (<term sem="Protein_molecule" id="T53" lex="RAR_beta">RAR beta</term>) or an inhibitory activity (<term sem="Protein_molecule" id="T54" lex="RAR_gamma">RAR gamma</term> and <term sem="Protein_molecule" id="T55" lex="type_II_TGase">type II <term sem="Protein_molecule" id="T56" lex="TGase">TGase</term></term>).</sentence>
<event id="E9">
<type class="Gene_expression" />
<theme idref="T25" />
<clue>We here report that (i) like PML-RAR alpha <clueType>expression</clueType>, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E10">
<type class="Gene_expression" />
<theme idref="T27" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha <clueType>expression</clueType> blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E11">
<type class="Cell_differentiation" />
<theme idref="T29" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal <clueType>differentiation</clueType> <linkTheme>of</linkTheme> hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E12">
<type class="Cell_differentiation" />
<theme idref="T30" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal <clueType>differentiation</clueType> <linkTheme>of</linkTheme> hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E13">
<type class="Regulation" />
<theme idref="E11" />
<cause idref="T31" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E14">
<type class="Regulation" />
<theme idref="E11" />
<cause idref="A101" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E15">
<type class="Regulation" />
<theme idref="E11" />
<cause idref="T33" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E16">
<type class="Regulation" />
<theme idref="E12" />
<cause idref="T31" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E17">
<type class="Regulation" />
<theme idref="E12" />
<cause idref="A101" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E18">
<type class="Regulation" />
<theme idref="E12" />
<cause idref="T33" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) <linkCause>in response to</linkCause> different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E19">
<type class="Negative_regulation" />
<theme idref="E13" />
<cause idref="E9" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E20">
<type class="Negative_regulation" />
<theme idref="E13" />
<cause idref="E10" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E21">
<type class="Negative_regulation" />
<theme idref="E14" />
<cause idref="E9" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E22">
<type class="Negative_regulation" />
<theme idref="E14" />
<cause idref="E10" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E23">
<type class="Negative_regulation" />
<theme idref="E15" />
<cause idref="E9" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E24">
<type class="Negative_regulation" />
<theme idref="E15" />
<cause idref="E10" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E25">
<type class="Negative_regulation" />
<theme idref="E16" />
<cause idref="E9" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E26">
<type class="Negative_regulation" />
<theme idref="E16" />
<cause idref="E10" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E27">
<type class="Negative_regulation" />
<theme idref="E17" />
<cause idref="E9" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E28">
<type class="Negative_regulation" />
<theme idref="E17" />
<cause idref="E10" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E29">
<type class="Negative_regulation" />
<theme idref="E18" />
<cause idref="E9" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E30">
<type class="Negative_regulation" />
<theme idref="E18" />
<cause idref="E10" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression <clueType>blocks</clueType> terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E31">
<type class="Regulation" />
<theme idref="T37" />
<cause idref="A7" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA <clueType>sensitivity</clueType> <linkTheme>of</linkTheme> hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>SENSITIVITY</comment>
</event>
<event id="E32">
<type class="Positive_regulation" />
<theme idref="E31" />
<cause idref="T34" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, <clueType>increases</clueType> RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event assertion="non-exist" id="E33">
<type class="Positive_regulation" />
<theme idref="E31" />
<cause idref="T35" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, <clueType>increases</clueType> RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event assertion="non-exist" id="E34">
<type />
<theme idref="A10" />
<cause idref="A9" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-<clueType>resistant</clueType> hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>RESISTANCE</comment>
</event>
<event id="E35">
<type class="Regulation" />
<theme idref="T39" />
<cause idref="A8" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA <clueType>sensitivity</clueType> <linkTheme>of</linkTheme> RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
<comment>SENSITIVITY</comment>
</event>
<event assertion="non-exist" id="E36">
<type class="Regulation" />
<theme idref="E35" />
<cause idref="T34" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and <clueType>restores</clueType> RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E37">
<type class="Binding" />
<theme idref="T40" />
<theme idref="T42" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA <clueType>binding affinities</clueType>; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E38">
<type class="Binding" />
<theme idref="T41" />
<theme idref="T42" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA <clueType>binding affinities</clueType>; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E39">
<type class="Regulation" />
<theme idref="T45" />
<cause idref="T44" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA <clueType>response</clueType> <linkTheme>of</linkTheme> RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E40">
<type class="Positive_regulation" />
<theme idref="E39" />
<cause idref="T43" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha <clueType>enhances</clueType> the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E41">
<type class="Gene_expression" />
<theme idref="T52" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha <clueType>expression</clueType> has either no effect (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event assertion="non-exist" id="E42">
<type class="Regulation" />
<theme idref="T53" />
<cause idref="E41" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no <clueType>effect</clueType> (RAR beta) or an inhibitory activity (RAR gamma and type II TGase).</clue>
</event>
<event id="E43">
<type class="Negative_regulation" />
<theme idref="T54" />
<cause idref="E41" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an <clueType>inhibitory activity</clueType> (RAR gamma and type II TGase).</clue>
</event>
<event id="E44">
<type class="Negative_regulation" />
<theme idref="T55" />
<cause idref="E41" />
<clue>We here report that (i) like PML-RAR alpha expression, PLZF-RAR alpha expression blocks terminal differentiation of hematopoietic precursor cell lines (U937 and HL-60) in response to different stimuli (vitamin D3, transforming growth factor beta1, and dimethyl sulfoxide); (ii) PML-RAR alpha, but not PLZF-RAR alpha, increases RA sensitivity of hematopoietic precursor cells and restores RA sensitivity of RA-resistant hematopoietic cells; (iii) PML-RAR alpha and PLZF-RAR alpha have similar RA binding affinities; and (iv) PML-RAR alpha enhances the RA response of RA target genes (those for RAR beta, RAR gamma, and transglutaminase type II [TGase]) in vivo, while PLZF-RAR alpha expression has either no effect (RAR beta) or an <clueType>inhibitory activity</clueType> (RAR gamma and type II TGase).</clue>
</event>
<sentence id="S5">These data demonstrate that <term sem="Protein_molecule" id="T57" lex="PML-RAR_alpha">PML-RAR alpha</term> and <term sem="Protein_molecule" id="T58" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term> have similar (inhibitory) effects on <term sem="Other" id="T59" lex="RA-independent_differentiation"><term sem="Organic_compound_other" id="A11">RA</term>-independent <term sem="Other" id="A12">differentiation</term></term> and opposite (stimulatory or inhibitory) effects on <term sem="Other" id="T60" lex="RA-dependent_differentiation"><term sem="Organic_compound_other" id="T61" lex="RA">RA</term>-dependent <term sem="Other" id="A13">differentiation</term></term> and that they behave in vivo as <term sem="DNA_domain_or_region" id="T62" lex="RA-dependent_enhancer"><term sem="Organic_compound_other" id="T63" lex="RA">RA</term>-dependent enhancers</term> or inhibitors of <term sem="DNA_family_or_group" id="T64" lex="RA-responsive_gene"><term sem="Organic_compound_other" id="T65" lex="RA">RA</term>-responsive <term sem="DNA_family_or_group" id="A14">genes</term></term>, respectively.</sentence>
<event assertion="non-exist" id="E45">
<type class="Positive_regulation" />
<theme idref="A12" />
<cause idref="A11" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-<clueType>independent</clueType> differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E46">
<type class="Negative_regulation" />
<theme idref="E45" />
<cause idref="T57" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have <clueType>similar (inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E47">
<type class="Negative_regulation" />
<theme idref="E45" />
<cause idref="T58" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have <clueType>similar (inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E48">
<type class="Positive_regulation" />
<theme idref="A13" />
<cause idref="T61" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-<clueType>dependent</clueType> differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E49">
<type class="Positive_regulation" />
<theme idref="E48" />
<cause idref="T57" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and <clueType>opposite (stimulatory or inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E50">
<type class="Negative_regulation" />
<theme idref="E48" />
<cause idref="T58" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and <clueType>opposite (stimulatory or inhibitory) effects</clueType> <linkTheme>on</linkTheme> RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E51">
<type class="Positive_regulation" />
<cause idref="T57" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that <corefCause>they</corefCause> behave in vivo as RA-dependent <clueType>enhancers</clueType> or inhibitors of RA-responsive genes, respectively.</clue>
<comment>NO THEME</comment>
</event>
<event id="E52">
<type class="Positive_regulation" />
<cause idref="T58" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that <corefCause>they</corefCause> behave in vivo as RA-dependent <clueType>enhancers</clueType> or inhibitors of RA-responsive genes, respectively.</clue>
<comment>NO THEME</comment>
</event>
<event id="E54">
<type class="Positive_regulation" />
<theme idref="E51" />
<cause idref="T63" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-<clueType>dependent</clueType> enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E55">
<type class="Positive_regulation" />
<theme idref="E52" />
<cause idref="T63" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-<clueType>dependent</clueType> enhancers or inhibitors of RA-responsive genes, respectively.</clue>
</event>
<event id="E56">
<type class="Regulation" />
<theme idref="A14" />
<cause idref="T65" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or inhibitors of RA-<clueType>responsive</clueType> genes, respectively.</clue>
</event>
<event id="E57">
<type class="Negative_regulation" />
<theme idref="E56" />
<cause idref="T57" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or <clueType>inhibitors</clueType> <linkTheme>of</linkTheme> RA-responsive genes, respectively.</clue>
</event>
<event id="E58">
<type class="Negative_regulation" />
<theme idref="E56" />
<cause idref="T58" />
<clue>These data demonstrate that PML-RAR alpha and PLZF-RAR alpha have similar (inhibitory) effects on RA-independent differentiation and opposite (stimulatory or inhibitory) effects on RA-dependent differentiation and that they behave in vivo as RA-dependent enhancers or <clueType>inhibitors</clueType> <linkTheme>of</linkTheme> RA-responsive genes, respectively.</clue>
</event>
<sentence id="S6">Their different activities on the <term sem="Other" id="T66" lex="RA_signalling_pathway"><term sem="Organic_compound_other" id="T67" lex="RA">RA</term> signalling pathway</term> might underlie the different responses of <term sem="Other" id="A16"><term sem="Protein_molecule" id="T68" lex="PML-RAR_alpha">PML-RAR alpha</term></term> and <term sem="Other" id="A17"><term sem="Protein_molecule" id="T69" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term></term> <term sem="Other" id="T70" lex="APL">APLs</term> to <term sem="Other" id="T71" lex="RA_treatment"><term sem="Organic_compound_other" id="A15">RA</term> treatment</term>.</sentence>
<event id="E59">
<type class="Regulation" />
<theme idref="T66" />
<cause idref="T57" />
<clue><corefCause>Their</corefCause> different <clueType>activities</clueType> <linkTheme>on</linkTheme> the RA signalling pathway might underlie the different responses of PML-RAR alpha and PLZF-RAR alpha APLs to RA treatment.</clue>
</event>
<event id="E60">
<type class="Regulation" />
<theme idref="T66" />
<cause idref="T58" />
<clue><corefCause>Their</corefCause> different <clueType>activities</clueType> <linkTheme>on</linkTheme> the RA signalling pathway might underlie the different responses of PML-RAR alpha and PLZF-RAR alpha APLs to RA treatment.</clue>
</event>
<event id="E61">
<type class="Artificial_process" />
<theme idref="A15" />
<clue>Their different activities on the RA signalling pathway might underlie the different responses of PML-RAR alpha and PLZF-RAR alpha APLs to RA <clueType>treatment</clueType>.</clue>
</event>
<event id="E62">
<type class="Regulation" />
<theme idref1="T70" idref="A16" />
<cause idref="E61" />
<clue>Their different activities on the RA signalling pathway might underlie the different <clueType>responses</clueType> <linkTheme>of</linkTheme> PML-RAR alpha and PLZF-RAR alpha APLs <linkCause>to</linkCause> RA treatment.</clue>
</event>
<event id="E63">
<type class="Regulation" />
<theme idref1="T70" idref="A17" />
<cause idref="E61" />
<clue>Their different activities on the RA signalling pathway might underlie the different <clueType>responses</clueType> <linkTheme>of</linkTheme> PML-RAR alpha and PLZF-RAR alpha APLs <linkCause>to</linkCause> RA treatment.</clue>
</event>
<sentence id="S7">The <term sem="Protein_molecule" id="T72" lex="PLZF-RAR_alpha_fusion_protein"><term sem="Protein_molecule" id="T73" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term> fusion protein</term> contains an approximately <term sem="Protein_domain_or_region" id="T74" lex="120-amino-acid_N-terminal_motif">120-amino-acid N-terminal motif</term> (called the <term sem="Protein_domain_or_region" id="T75" lex="POZ_domain">POZ domain</term>), which is also found in a variety of zinc finger proteins and a group of <term sem="Protein_family_or_group" id="T76" lex="poxvirus_protein"><term sem="Virus" id="T77" lex="poxvirus">poxvirus</term> proteins</term> and which mediates <term sem="Other" id="T78" lex="protein-protein_interaction">protein-protein interactions</term>.</sentence>
<event id="E64">
<type class="Correlation" />
<theme idref="T57" />
<theme idref="T58" />
<clue>The PLZF-RAR alpha fusion protein contains an approximately 120-amino-acid N-terminal motif (called the POZ domain), which is also found in a variety of zinc finger proteins and a group of poxvirus proteins and which mediates <corefTheme idref1="T57">protein</corefTheme>-<corefTheme idref1="T58">protein</corefTheme> <clueType>interactions</clueType>.</clue>
</event>
<event id="E65">
<type class="Positive_regulation" />
<theme idref="E64" />
<cause idref="T75" />
<clue>The PLZF-RAR alpha fusion protein contains an approximately 120-amino-acid N-terminal motif (called the POZ domain), which is also found in a variety of zinc finger proteins and a group of poxvirus proteins and which <clueType>mediates</clueType> protein-protein interactions.</clue>
</event>
<sentence id="S8">Deletion of the <term sem="Protein_domain_or_region" id="T79" lex="PLZF_POZ_domain">PLZF <term sem="Protein_domain_or_region" id="T80" lex="POZ_domain">POZ domain</term></term> partially abrogated the inhibitory effect of <term sem="Protein_molecule" id="T81" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term> on <term sem="Other" id="T82" lex="RA-induced_differentiation"><term sem="Organic_compound_other" id="A18">RA</term>-induced <term sem="Other" id="A19">differentiation</term></term> and on <term sem="Other" id="T83" lex="RA-mediated_type_II_TGase_up-regulation"><term sem="Organic_compound_other" id="A20">RA</term>-mediated <term sem="Protein_family_or_group" id="T84" lex="type_II_TGase">type II TGase</term> up-regulation</term>, suggesting that <term sem="Other" id="T85" lex="POZ-mediated_protein_interaction"><term sem="Protein_domain_or_region" id="A21">POZ</term>-mediated protein interactions</term> might be responsible for the inhibitory transcriptional activities of <term sem="Protein_molecule" id="T86" lex="PLZF-RAR_alpha">PLZF-RAR alpha</term>.</sentence>
<event id="E66">
<type class="Mutagenesis" />
<theme idref="T79" />
<clue><clueType>Deletion</clueType> <linkTheme>of</linkTheme> the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
<comment>ARTIFICIAL</comment>
</event>
<event id="E67">
<type class="Positive_regulation" />
<theme idref="A19" />
<cause idref="A18" />
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-<clueType>induced</clueType> differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E68">
<type class="Positive_regulation" />
<theme idref="T84" />
<cause idref="A20" />
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-<linkCause>mediated</linkCause> type II TGase <clueType>up-regulation</clueType>, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E69">
<type class="Negative_regulation" />
<theme idref="E67" />
<cause idref="T81" />
<clue>Deletion of the PLZF POZ domain partially abrogated the <clueType>inhibitory effect</clueType> <linkCause>of</linkCause> PLZF-RAR alpha <linkTheme>on</linkTheme> RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E70">
<type class="Negative_regulation" />
<theme idref="E68" />
<cause idref="T81" />
<clue>Deletion of the PLZF POZ domain partially abrogated the <clueType>inhibitory effect</clueType> <linkCause>of</linkCause> PLZF-RAR alpha on RA-induced differentiation and <linkTheme>on</linkTheme> RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E71">
<type class="Positive_regulation" />
<theme idref="E64" />
<cause idref="A21" />
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-<clueType>mediated</clueType> <corefTheme>protein interactions</corefTheme> might be responsible for the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
<event id="E72">
<type class="Negative_regulation" />
<cause idref="T86" />
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be responsible for the <clueType>inhibitory transcriptional activities</clueType> <linkCause>of</linkCause> PLZF-RAR alpha.</clue>
<comment>NO THEME</comment>
</event>
<event uncertainty="probable" id="E73">
<type class="Regulation" />
<theme idref="E72" />
<cause idref="E71" />
<clue>Deletion of the PLZF POZ domain partially abrogated the inhibitory effect of PLZF-RAR alpha on RA-induced differentiation and on RA-mediated type II TGase up-regulation, suggesting that POZ-mediated protein interactions might be <clueType>responsible</clueType> <linkTheme>for</linkTheme> the inhibitory transcriptional activities of PLZF-RAR alpha.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
